Navigation Links
News briefs from the October issue of Chest
Date:10/6/2009

VENTILATION MASK LEAKAGE MAY CONTAMINATE HOSPITAL ROOM

New research shows that certain noninvasive positive pressure ventilation (NPPV) masks may leak exhaled air up to a distance of 1 m from patients receiving treatments. This finding raises concerns about the potential spread of highly contagious respiratory illness within the hospital setting. Using a patient simulator that mimicked a patient with mild lung injury, researchers from Hong Kong measured the exhaled air leakage from two different face masks. Inspiratory pressure (IPAP) was gradually increased while expiratory pressure remained the same. Results showed that there was substantial exposure to exhaled air within a 1 m region of the patient receiving treatment. In addition, results showed that higher IPAP resulted in higher contamination. Researchers suggest that health-care workers take adequate precautions when providing NPPV support to patients with highly contagious or unknown respiratory conditions. This study is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

UNCONTROLLED ASTHMA PREVALENT AMONG MINORITY CHILDREN

African-American and Hispanic children have a high incidence of uncontrolled asthma, compared with Caucasian children with asthma. Using data from the National Asthma Survey, researchers from the Centers for Disease Control and Prevention assessed symptom control, medication use, and health-care utilization among 1,485 Caucasian (55 percent), African-American (20 percent) and Hispanic (25 percent) children with current asthma who reside in Alabama, California, Illinois, or Texas. The analysis showed that, compared with Caucasian children, African-American and Hispanic children had more indicators of poorly controlled asthma, including increased emergency health-care utilization, more daily rescue medication use, and less use of inhaled corticosteroids. The article is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

LABAs/ICS COMBINATION THERAPY MAY DO MORE HARM THAN GOOD

Current guidelines recommend the use of inhaled corticosteroids (ICS) in combination with long-acting beta agonists (LABAs) to reduce the frequency of exacerbations in symptomatic patients with severe to very severe chronic obstructive pulmonary disease (COPD). However, new research shows that this combination therapy may not provide significant benefits for patients and may cause adverse events. Researchers from Spain, Chile, and Uruguay reviewed 18 randomized controlled trials with 12,446 participants where the primary outcomes were COPD exacerbations and mortality. The analysis showed that therapy with LABAs/ICS did not decrease severe exacerbation or all-cause or respiratory mortality; however, moderate exacerbations were significantly reduced. Furthermore, the combination therapy was associated with an increased risk of pneumonia. This article is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum
3. News briefs from the November issue of Chest
4. DuPont Group Vice President Briefs Investors on Performance Materials Segment
5. Nanotech Briefs Announces Call for Nominations for the Fourth Annual Nano 50(TM) Awards
6. News Briefs from Preventive Medicine 2008
7. Journal Chest -- March 2008 news briefs
8. News briefs: May issue of the journal Chest
9. Weill Cornell science briefs May 2008
10. News briefs from the American Society of Plastic Surgeons
11. News briefs from the American Society of Plastic Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: